{
  "resourceType": "ValueSet",
  "id": "shr-oncology-BrcaReceptorStatusVS",
  "text": {
    "status": "generated",
    "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n<p><b>SHR BrcaReceptorStatusVS ValueSet</b></p>\n<p>Classification of receptor status in breast cancer.</p>\n</div>"
  },
  "url": "http://standardhealthrecord.org/shr/oncology/vs/BrcaReceptorStatusVS",
  "identifier": [
    {
      "system": "http://standardhealthrecord.org",
      "value": "shr.oncology.BrcaReceptorStatusVS"
    }
  ],
  "version": "0.0.1",
  "name": "SHR BrcaReceptorStatusVS ValueSet",
  "title": "SHR BrcaReceptorStatusVS ValueSet",
  "status": "draft",
  "date": "2017-12-20",
  "publisher": "The MITRE Corporation: Standard Health Record Collaborative",
  "contact": [
    {
      "telecom": [
        {
          "system": "url",
          "value": "http://standardhealthrecord.org"
        }
      ]
    }
  ],
  "description": "Classification of receptor status in breast cancer.",
  "compose": {
    "include": [
      {
        "system": "http://standardhealthrecord.org/shr/oncology/cs/BrcaReceptorStatusCS",
        "concept": [
          {
            "code": "luminal_A",
            "display": "Group 1. Includes tumors that are ER positive and PR positive, but negative for HER2. Luminal A breast cancers are likely to benefit from hormone therapy and may also benefit from chemotherapy."
          },
          {
            "code": "luminal_B",
            "display": "Group 2. Includes tumors that are ER positive, PR negative and HER2 positive. Luminal B breast cancers are likely to benefit from chemotherapy and may benefit from hormone therapy and treatment targeted to HER2."
          },
          {
            "code": "HER2_positive",
            "display": "Group 3. Includes tumors that are ER negative and PR negative, but HER2 positive. HER2 breast cancers are likely to benefit from chemotherapy and treatment targeted to HER2."
          },
          {
            "code": "Triple_negative",
            "display": "Group 4. Also called basal-like breast cancer, includes tumors that are ER negative, PR negative and HER2 negative. Basal-like breast cancers are likely to benefit from chemotherapy."
          }
        ]
      }
    ]
  }
}